Biopharma News : Biopharma and Pharma news from all around the world :
- AHF Receives Expedited Florida Hearing Opposing ADAP Reductions
- The Cannabist Company Enters Into Forbearance Agreement With Senior Secured Noteholders
- Bial Achieves Key Milestone in Phase 2b ACTIVATE Study of BIA 28-6156 in GBA1-Associated Parkinson’s Disease
- Tubulis Adds Steve Kelsey as Independent Director to its Advisory Board
- Announcing the 2026 I.D.E.A.L. Bioscience Employers: Turning Action into Impact
- Genentech Announces Positive Phase II Results for Its Dual GLP-1/GIP Receptor Agonist CT-388 in People Living With Obesity
- MindWalk Applies HYFT® Technology to Detect Functional Adjacency Linked to Portfolio Risk in AI-Designed Therapeutics
- A Practical Approach to Developing the CMC Package for Veterinary Pharmaceutical Products | 1-Day Online Training Course (May 7, 2026) – Master EU CMC Requirements for Veterinary Pharmaceuticals – ResearchAndMarkets.com
- Serenity Mental Health Centers Offers Breakthrough Ketamine Therapy in Las Vegas
- Prospera™ Featured in Landmark Interventional Study Advancing Lung Transplant Care
- Genethon Advances Groundbreaking Gene Therapies for Patients with Rare Genetic Diseases
- Aesyra Demonstrates Significant Sleep Bruxism Reduction in Clinical Study
- Samsung Epis Holdings Reports Fourth Quarter and Fiscal Year 2025 Financial Results
- Merz Therapeutics Submits Application to the European Medicines Agency for New Indication of XEOMIN® in Pediatric Spasticity
- Flunitrazepam (CAS 1622-62-4) Industry Research 2025: Global and Regional Market Trends 2019-2024 and Forecasts 2025-2029 – Applications, Manufacturing Method, Patents, Suppliers, Prices, End-users – ResearchAndMarkets.com
- Flumazenil (CAS 78755-81-4) Industry Research 2025: Global and Regional Market Trends 2019-2024 and Forecasts 2025-2029 – Applications, Manufacturing Method, Patents, Suppliers, Prices, End-users – ResearchAndMarkets.com
- Prodalim Expands SOLOS Capabilities with New Dealcoholization Site in Spain
- ENHERTU® Plus Pertuzumab Type II Variation Application Validated in the EU as First-Line Treatment of Patients with HER2 Positive Metastatic Breast Cancer
- Median Technologies Reports Landmark 2025 Performance With Major Regulatory and Commercial Milestones Ahead in 2026
- Organon Announces US Food and Drug Administration Approval of Supplemental New Drug Application Extending Duration of Use of NEXPLANON® (etonogestrel implant) 68 mg Radiopaque
- DiaMedica Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Repare Shareholders Approve Acquisition by XenoTherapeutics, Inc.
- Bayer welcomes the U.S. Supreme Court decision to review the Durnell case in the Roundup™ litigation
- Emmecell Appoints Ramin Valian as Chief Executive Officer to Advance Magnetic Cell Delivery Platform
- AGC Biologics Celebrates U.S. and EU Approval of Fondazione Telethon’s Waskyra™ Treatment for Wiskott-Aldrich Syndrome
- Genmab Announces Topline Results for Epcoritamab (DuoBody® CD3xCD20) from Phase 3 EPCORE® DLBCL-1 Trial in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
- Fluoxetine Hydrochloride (CAS 56296-78-7) Industry Research 2025: Global Market Trends 2019-2024 and Forecasts 2025-2029 – Applications, Manufacturing Method, Patents, Suppliers, Prices, End-users – ResearchAndMarkets.com
- Brotizolam (CAS 57801-81-7) Industry Research 2025: Global Market Trends 2019-2024 and Forecasts 2025-2029 – Applications, Manufacturing Method, Patents, Suppliers, Prices, End-users – ResearchAndMarkets.com
- BeOne Medicines Highlights Global Oncology Leadership at 44th Annual J.P. Morgan Healthcare Conference
- Vizient and AdventHealth Expand Agreement for Advanced Data and Digital Services
News about Biotech, Pharma, Biopharma, Medical Devices, Diagnostics, Digital Health
- Test Headline 30.01.26
- Test 2 Headline 30.01.26
- Heidelberg Pharma Received Development Milestone Payment from Partner Takeda
- Eckert & Ziegler on Track as Planned and Achieves Another Record Year in 2025
- Lonza Delivers Strong Profitable Growth in Full-Year 2025 and Successfully Completes Vacaville Site Integration
- MHH to Present Scientific Findings on Cold Plasma Therapy for Pulmonary Application at Press Conference in February 2026
- Siegfried to acquire high-quality small molecules drug substance capacity in the US
- DocMorris repurchases convertible bonds maturing in 2026 with a nominal value of around CHF 14.4 million
- Dr. Christian Schlögel nominated as new member of the Board of Directors
- SKAN announces preliminary key figures for the 2025 financial year
- Rentschler Biopharma appoints Detra Glinatsis as Head of Business Development U.S.
- Galenica continues to grow: sales increase to over CHF 4 billion
- Global momentum in the cannabis market: New signals from the U.S. strengthen long-term prospects for Europe and SYNBIOTIC
- Mallia Aesthetics selected as Innovation Tank finalist at IMCAS World Congress 2026
- ARTCLINE appoints Peter Llewellyn-Davies as Chairman of the Supervisory Board and accelerates commercialization of innovative sepsis therapy
- Rentschler Biopharma Announces Executive Board Changes and Next Phase of Corporate Strategy
- DocMorris achieves 11.1 per cent revenue growth in 2025 – strong fourth quarter
- Correction of a release from 19/01/2026, 11:45 CET/CEST – Viromed Medical AG: Ex-vivo lung study marks milestone for research and approval
- Invitation: Straumann Group full-year 2025 results webcast
- Viromed Medical AG: Ex-vivo lung study marks milestone for research and approval
- DOUGLAS AG: Preliminary results for Q1 2025/26 – adjusted EBITDA slightly below market expectation – full year guidance unchanged
- DOUGLAS Group delivers 1.7% sales growth in the first quarter amid challenging market environment
- Medios AG enters market for medicinal cannabis
- PolyPeptide successfully closes financial year 2025 with strong revenue growth and marked improvement in profitability
- Sigyn Therapeutics Issues Shareholder Update Highlighting the Advancement of CardioDialysis(TM) and New Corporate Initiatives
- Drägerwerk AG & Co. KGaA: Preliminary figures 2025: Record net sales and significant earnings growth – forecast for 2026
- Viromed Medical AG switches to registered shares
- RHÖN-KLINIKUM Aktiengesellschaft adjusts the EBITDA forecast for financial year 2025
- Mainz Biomed to Present Results of Pancreatic Cancer Verification Study at AACR 2026 Annual Meeting
- Sandoz confirms European Commission approval of Ondibta® (insulin glargine), strengthening overall biosimilars leadership and position in diabetes
- Oxford Healthspan to Introduce New Primeadine® GF Powder Through a ‘Longevity Shot’ Experience During Grammy Week in Los Angeles
- Enzon Announces Commencement of Exchange Offer Relating to Series C Non-Convertible Redeemable Preferred Stock in Connection With Viskase Merger
- Park Dental Partners Announces Dates for Fourth Quarter and Full Year 2025 Earnings Release and Conference Call
- Crescent Biopharma Announces Grants of Inducement Awards
- Achieve Life Sciences Announced Granting of New Hire Inducement Awards
- NurExone Appoints Eyal Gabbai to Board, Adding Large-Scale Healthcare System and Capital Markets Expertise
- Olema Oncology Announces Departure of Chief Operating and Financial Officer
- Tevogen Board to Evaluate Potential One-Time Special Cash Dividend to Shareholders
- Dr. Linette Williamson Expands Integrative Medicine Services in Encinitas With Physician-Supervised Ozone Sauna Therapy
- CrazyBulk: SARM Alternatives for Bulking, Strength and Performance or Just Hype?
- OKYO Pharma Announces Acceptance of Urcosimod Phase 2 Study Results for Presentation at Prestigious ASCRS Annual Meeting
- Elevar Therapeutics Announces FDA Acceptance of New Drug Application Resubmission for Rivoceranib in Combination with Camrelizumab as a First-line Systemic Treatment for Unresectable Hepatocellular Carcinoma
- Chiesi Global Rare Diseases and Protalix BioTherapeutics Receive Positive CHMP Opinion for an Additional Dosing Regimen of Every Four Weeks for Elfabrio® (pegunigalsidase alfa) in the EU
- Chiesi Global Rare Diseases and Protalix BioTherapeutics Receive Positive CHMP Opinion for an Additional Dosing Regimen of 2mg/kg Body Weight Every-Four-Weeks for Elfabrio® (pegunigalsidase alfa) ▼ in the EU
- Standard BioTools Completes Sale of SomaLogic to Illumina
- IO Biotech Provides Corporate Update
- Polaryx Therapeutics Announces Approval to List Common Stock on Nasdaq
- PhenQ 2026: OTC appetite suppressant search analysis for phentermine alternatives
- PhenQ 2026: OTC appetite suppressant search analysis for phentermine alternatives
- Lexicon Announces Pricing of Approximately $94.6 Million Public Offering and Concurrent Private Placement
- Lexicon Announces Pricing of Approximately $94.6 Million Public Offering and Concurrent Private Placement
- Orion publishes Financial Statement Release for 2025 and holds a webcast on 12 February 2026
- Orion publishes Financial Statement Release for 2025 and holds a webcast on 12 February 2026
- Idorsia to present long-term lucerastat data and kidney biopsy results at WORLDSymposium
- Idorsia to present long-term lucerastat data and kidney biopsy results at WORLDSymposium
- Vaxcyte Announces Pricing of $550 Million Public Offering
- MediciNova Announces 100 Patients Enrolled in SEANOBI Study Expanded-Access-Program (EAP) Evaluating MN‑166 (ibudilast) in ALS patients
- Altimmune Announces Closing of $75 Million Registered Direct Offering of Common Stock
- RECORDATI ANNOUNCES STRATEGIC COLLABORATION WITH MODERNA TO DEVELOP AND COMMERCIALIZE WORLDWIDE mRNA 3927 FOR THE TREATMENT OF PROPIONIC ACIDEMIA
- Lexicon Announces Proposed Public Offering of Common Stock
Sources for this page of Biopharma News : biopharma-reporter.com and worldpharmanews and pharmatimes.com and drugs.com and fiercepharma.com and scripintelligence.com and PR Newswire and Business Wire. Please visit all this very interesting websites for more info.
Biopharma News – Pharma News